Ischemic stroke and coronary heart disease (CHD) share many vascular risk factors (e.g., hypertension),^[@R1],[@R2]^ with 20%--30% of stroke patients having symptomatic CHD and another 40% having silent cardiac ischemia.^[@R3]^ Although cardiac evaluation among patients with acute or subacute stroke largely focuses on discerning whether an event was caused by a cardioembolic source,^[@R4]^ the American Heart Association/American Stroke Association (AHA/ASA) also recommends consideration of cardiac screening for asymptomatic CHD based on a high-risk Framingham Cardiac Risk Score (FCRS ≥20%).^[@R3],[@R5][@R6][@R7]^

Investigating the presence of occult CHD among patients with cerebrovascular disease may be clinically prudent, given that CHD is a leading cause of morbidity and mortality in this population.^[@R3],[@R5][@R6][@R9]^ Determining whether patients with cerebrovascular disease also have coronary atherosclerotic disease may have important treatment implications,^[@R1],[@R10],[@R11]^ but a previous study attempting to implement this guideline found that outpatient providers did not pursue testing, given the lack of evidence regarding whether such screening improved poststroke outcomes.^[@R6]^

In the absence of a prospective study to ascertain whether implementation of cardiac screening among patients with a recent cerebrovascular event improves outcomes, we used administrative data to determine whether (1) patients with cerebrovascular disease routinely received cardiac stress testing based on a high-risk FCRS and (2) screening for asymptomatic CHD was associated with reduced 1-year all-cause mortality. We also conducted chart reviews to identify reasons why clinicians pursued cardiac stress testing.

Methods {#s1}
=======

Overview {#s1-1}
--------

This study was a secondary analysis of Veterans Health Administration (VA) administrative data, which were used to identify Veterans (n = 11,306) with a primary diagnosis of acute ischemic stroke or TIA who presented to a VA emergency department or were admitted to a VA medical center in fiscal year (FY) 2011 (i.e., October 2010--September 2011). We excluded patients (n = 6,097) based on medical history of CHD, myocardial infarction (MI), angina/chest pain, or receipt of percutaneous transluminal coronary angioplasty/percutaneous coronary intervention within the previous 5 years (as identified by a combination of ICD-9 and Common Procedural Terminology \[CPT\] codes); cardiac stress test within the 18 months prior to their stroke/TIA event^[@R12],[@R13]^; death within the 90 days of discharge or discharge to hospice; transfer to a non-VA acute care facility; or missing/unknown race. These exclusions were not mutually exclusive. The final analytic sample included 4,391 Veterans.

Standard protocol approvals, registrations, and patient consents {#s1-2}
----------------------------------------------------------------

Institutional review board approval was obtained for this research.

Data {#s1-3}
----

Data for demographic factors, medical comorbidities (e.g., CHD and MI), symptoms (e.g., angina/chest pain), and discharge medications were obtained from existing VA data sources: VHA Austin and fee-basis (which captures data related to Veterans receiving care outside of VHA medical centers) inpatient and outpatient data files in the 5 years pre cerebrovascular event (FY 2005--2012); a combination of ICD and CPT codes were used to identify medical history variables. Race/ethnicity data were collected from the Centers for Medicare and Medicaid Services (CMS) vital status file and if missing or unavailable, supplemented with data from the VA\'s Functional Status Outcomes Database and VHA Austin inpatient and outpatient data files, if available. Only 1% of race values were unknown and these patients were excluded from the analyses because calculation of the FCRS requires race.

FCRS was calculated for each patient based on race- and sex-specific pooled cohort equations that accounted for age, sex, race, total and high-density lipoprotein (HDL) cholesterol, systolic blood pressure (SBP; including treated or untreated), diabetes, and current smoking status. The results are used to estimate an individual\'s 10-year risk of cardiovascular event, and can be reliably and accurately calculated from administrative data.^[@R14],[@R15]^ SBP, total cholesterol, and HDL cholesterol values were based on values at discharge from the index stroke or TIA event when available; if no discharge measurement was available, the most recent value prior to discharge was used (table e-1, [links.lww.com/CPJ/A25](http://links.lww.com/CPJ/A25)). Pharmacy Benefits Management data were used to identify medications (e.g., antihypertensive medications), Corporate Data Warehouse data for blood pressure, and laboratory data for total and HDL cholesterol.

Data for covariates related to indications other than a high FCRS (e.g., troponin I \> 0.1 mcg/L) were collected 180 days prior to the cerebrovascular event and within 90 days after the index. Angina/chest pain prior to the index event was an exclusion to initial cohort construction; therefore, this covariate reflects angina/chest pain that occurred within 90 days of the index cerebrovascular event.

The primary outcome of interest was receipt of any cardiac stress testing, either pharmacologic (e.g., gated Persantine study) or nonpharmacologic (e.g., treadmill stress test) among high-risk patients within 90 days of hospital discharge. ICD-9 and CPT codes were used to identify cardiac stress testing (table e-2, [links.lww.com/CPJ/A25](http://links.lww.com/CPJ/A25)). Receipt of cardiac stress testing was identified using VA administrative data, linked VA CMS data, and VA fee-basis files; the combination of these data sources allowed for identification of testing provided for patients performed within and outside of the VA.

The secondary outcome of interest was all-cause 1-year poststroke mortality, as measured from the VA\'s Vital Status File (VSF). The VA VSF contains dates of death from all VA beneficiaries. Death information in the VA VSF originates from a variety of VA and non-VA sources (e.g., CMS). Research has shown that the VA VSF is relatively complete and accurate when compared with information contained in the National Death Index (NDI), with more than 98.3% of deaths in the VA VSF confirmed with deaths in the NDI.^[@R16]^ Given that our study population was assembled based on FY11 data, with mortality data being extracted at the end of FY13, enough time had elapsed to capture mortality events occurring 1 year after the index cerebrovascular event.

Data were also collected through retrospective chart review on a sample of electronic medical records to determine whether providers ordered stress testing based on a patient\'s high risk FCRS, and to collect other indications for (e.g., symptoms of chest pain or angina, preoperative evaluation for carotid endarterectomy \[CEA\]) and results of stress testing (e.g., positive dobutamine stress test in the area of left anterior descending artery). Chart reviews were performed by abstractors who were specially trained for the study.

Statistical analyses {#s1-4}
--------------------

We describe demographic and clinical characteristics of participants based on receipt of cardiac stress testing and for the overall study sample, using χ^2^ or Fisher exact tests for categorical variables and Wilcoxon rank-sum or *t* tests for continuous variables. We then compared these characteristics among patients with FCRS ≥20%, also based on receipt of stress testing. Two separate multivariable logistic regression models were used to examine (1) whether cardiac stress testing was performed more frequently for patients with FCRS ≥20% compared with patients with FCRS \<20% and (2) the association of receipt of cardiac stress testing and 1-year all-cause mortality among the entire cohort. A generalized linear mixed model with logit link was used to model both outcomes. A random intercept of VA facility was used to adjust for the correlation among patients within the same facility. Covariates associated with outcomes in the bivariate random effect model with *p* value \<0.25, or clinically important variables (e.g., FCRS), were included in the multivariable models, and nonsignificant covariates were dropped from the multivariable models one at a time. A ratio of 10 outcome events per variable was maintained during model construction.^[@R17],[@R18]^ For each regression model, discrimination (*C* statistics) was calculated to gauge model performance. Because missing data were rare, no imputations were made. Given that the low 1-year mortality among patients with FCRS ≥20% who received cardiac stress testing precluded a meaningful analysis of a population for which the AHA/ASA expert consensus guidelines recommend was intended, we also calculated the sample size required to have 80% statistical power, with a 2-sided α of 0.05, to detect a 20% difference in mortality among patients with a FCRS ≥20% who did and did not receive cardiac stress testing. All statistical analyses used SAS version 9.2 (SAS Institute, Cary, NC).

Data availability {#s1-5}
-----------------

Anonymized data not published within this article will be made available by request from any qualified investigator if approved by our Research Ethics Board. All analyses must be conducted behind the VA firewall. Investigators interested in working with the data should contact the authors.

Results {#s2}
=======

The mean age of the 4,391 patients in the study was 66.9 years (±SD 11.6) and 73.3% were not black; 3,067 had an ischemic stroke (69.8%) and 1,324 had a TIA (30.2%) as their index event ([table 1](#T1){ref-type="table"}). A high FCRS was calculated for 62.8% (2,759/4,391) of patients.

###### 

Patient characteristics at baseline, stratified by receipt of cardiac stress test^a^ (n = 4,391)

![](NEURCLINPRACT2017022319TT1)

![](NEURCLINPRACT2017022319TT1A)

Stress testing within 90 days of discharge occurred in 4.4% of all patients (195/4,391); the rate of stress testing was nearly identical among those with high and low/intermediate risk FCRS: 4.5% (123/2,759) for high and 4.4% (72/1,632) for low/intermediate FCRS. Patients receiving stress testing (compared with patients not receiving stress testing) were more likely to be not black with a history of hyperlipidemia, atrial fibrillation, congestive heart failure (CHF), carotid artery disease, CEA, elevated troponin I during admission, angina, lightheadedness, shortness of breath, abnormal ECG, and arrhythmia (other than atrial fibrillation), and to be prescribed antihypertensive and antiplatelet medications at discharge ([table 1](#T1){ref-type="table"}). Similar reasons for obtaining screening occurred in a sample restricted to high-risk patients ([table 2](#T2){ref-type="table"}). After adjusting for FCRS and sociodemographic and baseline characteristics, patients had a higher odds of receiving a cardiac stress test if they were not black, male, with a history of hyperlipidemia, diabetes, CHF, carotid artery disease, CEA, angina, lightheadedness, shortness of breath, abnormal ECG, or arrhythmia (other than atrial fibrillation). FCRS was not associated with receipt of stress testing in unadjusted or adjusted analyses (adjusted odds ratio \[aOR\] 0.77; confidence interval \[CI\] 0.54--1.10; [table 3](#T3){ref-type="table"}).

###### 

Baseline characteristics among patients with high Framingham cardiac risk score (n = 2,759)^a^
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###### 

Association between Framingham cardiac risk score and receipt of cardiac stress testing adjusted for patient characteristics at baseline (n = 4,391)

![](NEURCLINPRACT2017022319TT3)

Among the 4.4% (195/4,391) of patients receiving cardiac stress testing within 90 days of discharge, 3.6% (7/195) were dead at 1 year; 5.6% (234/4,196) of patients who did not receive stress testing were dead at 1 year. Neither unadjusted nor adjusted (aOR 0.59; 95% CI 0.26--1.30) analyses demonstrated an association between cardiac stress testing and mortality. Among the 62.8% (2,759/4,391) of patients with a high FCRS, 6.8% (188/2,759) were dead at 1 year; 3.3% (53/1,632) with a low/intermediate risk FCRS were dead at 1 year. High FCRS was associated with higher 1-year mortality (aOR 1.48; 95% CI 1.06--2.07; *p* \< 0.001; [table 4](#T4){ref-type="table"}).

###### 

Unadjusted and adjusted associations between cardiac screening 1-year mortality

![](NEURCLINPRACT2017022319TT4)

In a subsample (n = 3,099) of patients who did not have reasons to receive cardiac stress testing other than high FCRS (e.g., abnormal ECG), stress testing was not performed more commonly among patients with high FCRS compared to low/intermediate FCRS (2.5% vs 2.4%; *p* = 0.833). In contrast, patients who had other reasons for receiving cardiac stress testing more commonly had stress testing performed compared to those who did not have other reasons to receive stress testing (9.13% vs 2.48%; *p* \< 0.0001).

To detect a mortality difference among patients with FCRS ≥20% who did and did not receive cardiac stress testing, we estimated (for 50% screening prevalence) that 2,178 patients would be required in each group. In contrast, this analysis included 195 patients who received stress testing and 4,196 who did not receive testing.

In charts available for review (n = 17), chest pain/angina and preoperative/perioperative assessment for CEA/stent procedure or "other surgery" accounted for 53% (n = 9/17) of the cardiac screening indications; none of these procedures or surgeries was performed based on high-risk FCRS (table e-3, [links.lww.com/CPJ/A25](http://links.lww.com/CPJ/A25)).

Discussion {#s3}
==========

Cardiac stress testing for patients with cerebrovascular disease based on a high-risk FCRS is not performed as part of routine clinical care. Given our limited ability to model 1-year all-cause mortality among patients for whom the AHA/ASA expert consensus guideline recommends consideration of screening (i.e., FCRS ≥20%), we cannot comment on whether routine screening for high-risk patients with cerebrovascular disease should be performed from a mortality perspective. When examining the association among all patients with cerebrovascular disease irrespective of their FCRS, we found no mortality benefit for cardiac screening. We also identified important predictors of receiving cardiac stress testing.

Although the FCRS was originally intended to prognosticate 10-year risk of CHD-related events, it has been used to predict shorter-term outcomes among patients with cerebrovascular disease.^[@R5],[@R7]^ A high-risk FCRS has been shown to predict a higher hazard of MI (adjusted hazard ratio 3.70; 95% CI 2.14--6.38) and MI or vascular death (adjusted hazard ratio 2.21; 95% CI 1.48--3.28) among noncardioembolic poststroke patients.^[@R7]^ Our finding that high-risk FCRS was associated with higher 1-year mortality among our cohort of stroke and TIA patients is similar to another study demonstrating the association between increasing FCRS and likelihood of death and disability during an index admission with stroke.^[@R5]^

An important consideration regarding the implementation of CHD screening based on high-risk FCRS is the prevalence of CHD among asymptomatic patients. Prior studies have examined the prevalence of asymptomatic CHD in patients with cerebrovascular disease, with an estimated 20%--40% having silent cardiac ischemia as diagnosed by cardiac stress testing.^[@R19]^ When considering the prevalence of angiographically diagnosed CHD, 62% of patients with cerebrovascular disease and without CHD had coronary artery plaques, whereas 26% of patients had coronary artery stenosis ≥50%. These patients had markedly increased risk of vascular events despite receiving best medical management for asymptomatic CHD.^[@R20]^ Noting the potential importance of CHD and CHD-related events among patients with cerebrovascular disease, AHA/ASA Scientific Statement expert consensus guidelines recommended that providers should consider evaluating for occult CHD for patients with FCRS ≥20%.^[@R3]^

A study examining the implementation of this recommendation for poststroke CHD screening found that a minority of eligible patients received testing.^[@R6]^ When testing was performed, 14% of patients had a positive stress test, with these patients going on to be prescribed β-blockers.^[@R6]^ While we found that clinicians utilized cardiac stress testing for several approved indications (e.g., chest pain/angina),^[@R21],[@R22]^ our results also demonstrate relative underuse of stress testing among asymptomatic patients with cerebrovascular disease and high-risk FCRS.

In recent years, ischemic stroke, and more specifically atherosclerotic stroke, has appropriately been recognized as an important cardiac risk equivalent, given the association between stroke and the approximate ≥20% absolute risk of fatal or nonfatal MI or sudden death.^[@R23]^ Another rationale for considering ischemic stroke as a cardiac equivalent has been to promote the delivery of effective preventive strategies among all cardiac risk equivalents.^[@R23]^ This becomes especially important when considering that patients with cerebrovascular disease generally have poorer control of their vascular risk factors than patients with other cardiac equivalents.^[@R14],[@R24],[@R25]^

A key finding of these analyses was the identification of predictors of receiving cardiac stress testing. Not surprisingly, patients with well-established reasons to receive cardiac stress testing (e.g., angina/chest pain), conditions associated with increased vascular risk (e.g., hyperlipidemia), and carotid artery disease, as another cardiac equivalent, had a greater odds of receiving stress testing ([tables 1](#T1){ref-type="table"} and [3](#T3){ref-type="table"}).^[@R23]^ Although diabetes was associated with a higher odds of receiving cardiac screening in this cohort, a study conducted among patients with diabetes suggests that cardiac screening should not be pursued when the intent is to decrease cardiac event rates.^[@R24]^ Outside of the cerebrovascular literature, a lower burden of medical comorbidities was associated with an increased likelihood of receiving stress testing.^[@R26]^ One explanation for this finding is that patients with a greater degree of comorbidity may be "too sick" or have medical contraindications to undergo cardiac stress testing. We were surprised to detect racial differences related to receiving cardiac screening. Data from nonstroke populations indicate that black patients with cardiac disease are less likely to receive revascularization procedures both within^[@R27]^ and outside of the VA.^[@R28]^ Among Medicare beneficiaries, nonblack men are more likely to receive cardiac screening then black men.^[@R29]^ Possible explanations for our observed racial difference in cardiac stress testing among patients with a cerebrovascular event include race-based differences in access to care, perceptions of testing and procedures, and socioeconomic status. As the VA is not a fee-for-service enterprise, the ability of patients to pay for procedures is less likely to contribute to the observed racial disparity.

The strengths of our study include the large sample size and the ability to control for several important sociodemographic and baseline medical and neurologic conditions. Furthermore, chart review data helped to further illuminate reasons clinicians order cardiac stress testing for patients with cerebrovascular disease. Limitations of our study are worth noting. First, given that this is an observational study rather than a randomized controlled trial, we can only comment on associations rather than causation. Second, since few patients died in our sample who had both a FCRS ≥20% and cardiac screening, we were unable to adjust for other important predictors of mortality and therefore were unable to assess the association between cardiac screening and 1-year all-cause mortality among high-risk patients with cerebrovascular disease. As such, we were only able to examine a possible association between receiving CHD screening and mortality among all patients, rather than the subset of patients for which the consensus opinion was intended. Future work should examine whether the association between receipt of cardiac stress testing for asymptomatic CHD and mortality in an exclusively high-risk cerebrovascular disease population for several treatment implications related to vascular risk factor management. For example, recent cerebrovascular prevention guidelines recommend initiation of hydrochlorothiazide or angiotensin-converting enzyme inhibitor rather than β-blocker.^[@R1]^ β-blockers may less effectively prevent ischemic stroke in comparison to other agents, whereas they are the cornerstone of CHD treatment.^[@R11]^ Current CHD guidelines do not recommend the use of the combination aspirin/extended release dipyridamole,^[@R10]^ whereas there is Class I/Level of Evidence B for its use in stroke prevention.^[@R1]^ Third, we examined the relationship between all-cause mortality and receipt of stress testing rather than more cardiac-specific outcomes (e.g., coronary revascularization). Fourth, we cannot identify stroke subtype. Cardiac stress tests are more likely to be abnormal among patients with atherosclerotic-associated strokes compared with nonatherosclerotic strokes (50% vs 23%; *p* = 0.04).^[@R30]^ Patients with cerebrovascular events secondary to cardioembolic disease and those with carotid artery disease have been found to be at high risk of having occult CHD^[@R3]^; interestingly, etiologies leading to cardioembolic strokes and carotid artery disease were more prevalent among those who received cardiac screening. Finally, as our cohort comprises predominantly male Veterans, these results may be less generalizable to other populations.
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